New Oral Antibiotic Gepotidacin Shows Promise Against Drug-Resistant Gonorrhoea

Phase 3 clinical trials confirm gepotidacin's effectiveness against resistant gonorrhoea strains, with regulatory approval filings expected soon.

Gepotidacin, an oral antibiotic, demonstrated non-inferiority to the current standard injectable treatment for uncomplicated gonorrhoea in phase 3 clinical trials.
The drug has shown efficacy in treating gonorrhoea strains resistant to existing antibiotics, addressing a growing public health challenge.
Already FDA-approved for urinary tract infections, gepotidacin is anticipated to be submitted for regulatory approval for gonorrhoea within months.
The oral administration of gepotidacin offers potential advantages over injectable treatments, improving patient convenience and reducing healthcare resource demands.
Further research is needed to evaluate the drug's effectiveness in underrepresented populations and for extragenital infections, such as those in the throat and rectum.